Clinical Trial

Safety and Efficacy of FETO in CDH: A Phase III Trial

Study acronym: CHOP FETO
Recruiting
View on ClinicalTrials.gov →
Summary
Congenital diaphragmatic hernia (CDH) is a birth defect characterized by the development of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally. In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough before birth so these children are capable of surviving and thriving.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-13; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06884423
Lead Sponsor Holly L Hedrick, MD
Conditions Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Enrollment 80 participants
Start Date 2025-04-07
Primary Completion 2030-04 (estimated)
Study Completion 2032-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-22